Methotrexate-associated lymphoproliferative disorder in a patient with rheumatoid arthritis presenting in the skin

The risk of cancer in patients with psoriasis: A population-based cohort study in Taiwan

“…4,5 Broadband and narrowband UVB do not appear to increase the risk of squamous cell carcinoma. 36,37 Recently, development of lymphomas after methotrexate [38][39][40] and cyclosporine, [41][42][43][44][45][46][47] and remission of lymphomas after withdrawal of these drugs [48][49][50][51] in psoriasis patients have been reported. We demonstrated that PUVA and systemic therapies do not significantly increase the risk of cancer.…”

Methotrexate and psoriasis: 2009 National Psoriasis Foundation Consensus Conference

“…Lymphoma, particularly Epstein-Barr virus associated, and the reactivation of tuberculosis and hepatitis have all been reported. [23][24][25][26] A recent study showed a 50% increased risk of malignancy relative to the general population with a 3-fold increase in melanoma, 5-fold increase in non-Hodgkin lymphoma, and nearly 3-fold increase in lung cancer. 27 In short, clinicians need to have a high index of suspicion for any patient receiving immunosuppressive therapy.…”

Methotrexate-related lymphoproliferative disorder with extensive vascular involvement in a patient with rheumatoid arthritis

“…9,16,[19][20][21] Notably, the most characteristic finding of the current case was the extensive vascular damage. The tunica media of dermal arterioles was infiltrated by tumor cells.…”

“…17 This is also the case for MTX-LPD, as withdrawal of MTX could successfully induce a complete remission, although some cases required subsequent chemotherapies because of the unresponsiveness to the MTX withdrawal 9,15,16,19 or recurrences; subtypes of histologic morphologies may determine the clinical course. 19 A follow-up period of at least several weeks after the withdrawal of immunosuppressants is needed before considering the indication for a specific chemotherapy. 9 We thank Dr Keiko Miura, Division of Pathology, Tokyo Medical and Dental University, for useful suggestions.…”